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Abstract 5 
Background 6 
The potential of warfarin related harm is increased if clinicians lack the full patient specific 7 
information to make informed decisions – an e-proforma has been developed to communicate this 8 
information on hospital discharge. 9 
 10 
Objective 11 
To determine the views of general practitioners (GPs) on a warfarin discharge e-proforma.  12 
 13 
Method  14 
A cross-sectional survey of all GPs (n=272) within the Raigmore Hospital catchment area of NHS 15 
Highland, Scotland.   16 
 17 
Results 18 
The response rate was 39.3% (107/272). 84 (78.5%) noticed recent changes to information supplied 19 
on discharge for warfarin patients. 64 (59.8%) respondents thought this would result in more informed 20 
prescribing with regards to dosing, while 65 (60.7%) felt this would improve safety. Accurate 21 
 2 
completion, timely receipt of the e-proforma and a realistic date for subsequent INR tests were 1 
considered important by GPs. 2 
 3 
Conclusion 4 
This study suggests the use of an e-proforma to communicate information about a high-risk 5 
medication, warfarin, to GPs on discharge optimises safe, informed prescribing and monitoring in 6 
primary care. The development of a discharge e-proforma for other high-risk medication as a patient 7 
safety improvement measure should be explored. 8 
 9 
Impact of findings on clinical practice 10 
• Use of a warfarin prescribing e-proforma at discharge containing clinical information 11 
including; warfarin doses for 7 days prior to discharge and 7 days after, indication, duration of 12 
therapy, last INR result, target range and date for next INR test resulted in GPs believing they 13 
are able to prescribe warfarin more safely post-discharge. 14 
• Accurate and full completion of the e-proforma was a pre-requisite for GPs to perceive the 15 
patient safety benefits to be obtained. 16 
• The development of a discharge e-proforma for other high-risk medication as a patient safety 17 
improvement measure should be explored. 18 
 19 
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 21 
Introduction 22 
The Scottish Patient Safety Programme (SPSP) is a clinical governance and quality initiative which 23 
 3 
aims to reduce patient harm and improve outcomes. This programme has received wide critical 1 
acclaim, with Scotland perceived as the first country to undertake a national approach to delivering 2 
patient safety [1]. This approach was urgently warranted, evidenced from figures that around 10% of 3 
patients admitted to United Kingdom National Health Service (NHS) hospitals experience medicines 4 
related harm as a consequence of their admission, which could have been avoided in 50% of cases [2]. 5 
SPSP focuses on the use of evidence-based tools and practices to augment current systems thereby 6 
increasing quality [3]. One of the initial points of focus is to reduce potential harm to patients 7 
prescribed the oral anticoagulant warfarin. 8 
The term ‘integrated care’ relates to the prompt transfer of information where joint working between 9 
different healthcare professions is being employed to improve patient care [4]. However, there are 10 
some complex challenges involved in maintaining continuity of care between settings [5, 6]. These 11 
predominantly manifest as complications during the transfer of information between healthcare teams 12 
or by healthcare teams not effectively engaging and educating patients about their medication on 13 
discharge from hospital to primary care [7]. The risk to patients as a consequence of poor integrated 14 
care can result in preventable re-hospitalisations and harm to patients [8].  15 
The operational standard within Scotland is for anticoagulant prescribing and monitoring to be 16 
completed within primary care, supported by access to specialists if required. It is therefore 17 
imperative that the general practitioner (GP) has access to the most up-to-date information regarding 18 
warfarin therapy. As part of the SPSP programme, NHS Highland (a Scottish geographically remote 19 
and rural area) planned to improve the transfer of medication related information from hospital staff to 20 
GPs at the point of patient discharge for all patients admitted or commenced on warfarin during 21 
admission.  After receiving feedback from GPs regarding clinical information required to undertake 22 
warfarin management post-discharge safely, an e-proforma was added to the standard electronic 23 
Immediate Discharge Letter (IDL) ie discharge summary. There was a definitive need for an e-24 
proforma as full clinical information was not being communicated to GPs on discharge. The IDL, 25 
which originally reported - reason for admission; hospital treatment; duration of admission and 26 
medication on discharge - was modified to include a warfarin specific e-proforma, with fields of: 27 
 4 
warfarin doses for 7 days prior to discharge and 7 days after; indication; planned duration of therapy; 1 
last international normalised ratio (INR) result; target INR range; and date for next INR test. The e-2 
proforma was included in the IDL which is emailed to GP practices at the point of discharge. Also, a 3 
paper copy is printed on the ward for the patient. The warfarin discharge e-proforma was introduced 4 
in May 2010. 5 
 6 
Aim of the study 7 
The aim of this study was to determine the views of GPs on the utility of an e-proforma to 8 
communicate information regarding warfarin on discharge from hospital.  9 
 10 
Method 11 
A draft questionnaire was developed based upon anecdotal feedback from GPs regarding issues 12 
relating to medicines information transfer at the point of patient discharge. The draft questionnaire 13 
was reviewed for face and content validity by an expert panel of health service researchers before 14 
being piloted with two prescribing support pharmacists, two GPs and one practice nurse. The final 15 
questionnaire comprised items including: activities in prescribing and monitoring warfarin; views of 16 
the impact of the e-proforma on aspects of patient management; and suggested changes to the e-17 
proforma. Question types were a combination of closed, 5-point Likert scales and open response 18 
items.  19 
All GPs within the Raigmore Hospital catchment area, identified from the NHS Highland website 20 
(n=272), were included in the study. Each was mailed a study introductory letter, participant 21 
information leaflet, questionnaire and reply paid envelope. The questionnaires were numbered to 22 
allow follow-up of non-respondents who were sent up to two reminders at monthly intervals. Data 23 
collection took place between November 2011 and January 2012.  24 
 5 
Data were coded and entered into an SPSS database (SPSS Inc., Cary, NC version 21.0) and analysed 1 
using descriptive statistics to profile respondents and their questionnaire responses.  2 
The project was approved by the Ethical Review Panel of the School of Pharmacy and Life Sciences 3 
at Robert Gordon University, Aberdeen, United Kingdom. The North of Scotland Research Ethics 4 
Committee advised that NHS ethical review was not required. 5 
 6 
Results 7 
The response rate was 39.3% (107/272). Almost all were involved in managing warfarin patients after 8 
discharge, principally prescribing (90.7%, 97) and monitoring (88.8%, 95). The majority of 9 
respondents (78.5%, 84) reported awareness of changes to information provision following the 10 
introduction of the e-proforma, with the remainder largely commenting that they had not noticed any 11 
changes (12.1%, 13) or had yet to receive a e-proforma (3.7%, 4).  12 
 13 
Responses to statements relating to aspects of the warfarin IDL e-proforma are given in Table 1, 14 
highlighting the positive responses in terms of timeliness of information (52.3%, 56), improved 15 
decision making (59.8%, 64), easier management (50.5%, 54) and patient safety (60.7%, 65). In 16 
response to the question about warfarin stabilisation 49.5% (53) found there was no change in the ease 17 
by which patients could be stabilised on warfarin although 39.3% (42) found it easier given the 18 
additional information.  19 
 20 
<Insert Table 1 here> 21 
 22 
Data on specific aspects of information provision are given in Table 2, with positive responses on all 23 
aspects of warfarin management.  24 
 6 
 1 
<Insert Table 2 here> 2 
 3 
Almost one fifth of respondents (16.8%, 18) suggested additions to the information provided 4 
however, these suggestions related to the need for the data on the form to be complete and accurate ie 5 
the sections for INR results, specific dates for duration of treatment and need for lifelong treatment.  6 
The majority of respondents (71.0%, 76) commented that appropriate dates for GP INR testing were 7 
only discussed with GPs prior to patient discharge either occasionally or not at all. Some (16.8%, 18) 8 
stated that they were not able to access INR testing within the timescales stated on the e-proforma. 9 
This was due to issues including GP practice manpower, a requirement for a home visit or in some 10 
areas, the requirement for blood samples to be sent to central laboratory by post, all of which result in 11 
delays.  12 
 13 
Discussion 14 
The key findings of this study were that the GP respondents were generally positive about the e-15 
proforma, perceiving a beneficial impact on patient care. Several limitations of this study require that 16 
the findings are interpreted with caution. Although the 39% response rate was reasonable for a survey 17 
of GPs, the responses are based on self-reports and there was no attempt to determine the validity or 18 
reliability. However, despite these limitations, the findings are encouraging, with data provided from 19 
just under half of all GPs in the area, the vast majority of whom were directly involved in the 20 
management and prescribing of warfarin. The improvement in communication between secondary and 21 
primary care, specifically with regards to the trends in dosing and INR results, was cited as a key 22 
factor involved in this improvement. As a result over half felt that they were able to make more 23 
informed, safe, patient management decision in a timely manner regarding prescribing of warfarin as 24 
long as the e-proforma was accurately completed. In addition some minor changes to the form were 25 
 7 
suggested including specifying the dates pre- and post-discharge in addition to all previous INR 1 
results, not just the last INR. Despite this, half of GPs found there was no difference to the ease by 2 
which a patient may be stabilised on warfarin. This is likely to be as a result of the general difficulty 3 
involved with stabilising the INR for a patient prescribed warfarin. 4 
 5 
The use of a discharge proforma to communicate, completely, complex information has been shown 6 
to be effective for other clinical situations including after discharge for permanent pacemaker 7 
insertion [9]. While this study focused on the use of a discharge e-proforma to communicate 8 
information to GPs specifically about warfarin, the utility of an e-proforma should be explored for 9 
other high-risk medications to achieve integrated care and improve patient safety. A recent systematic 10 
review produced by a member of this research team has found a paucity of research on integrated care 11 
supported electronically [10]. Further work is warranted to determine the direct impact on patient care 12 
in terms of achieving desired patient outcomes and hospital readmissions. Also, an audit of the quality 13 
of completion of the e-proforma by hospital staff is planned. 14 
 15 
Conclusion 16 
The introduction of the discharge warfarin e-proforma as an addition to the IDL was perceived 17 
positively by GPs who considered that they were able to make more informed prescribing decisions 18 
with improvement in patient care. Such an approach could be applied to other high-risk medication to 19 
fully achieve integrated care. 20 
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Table 1 – GP views on communication of information regarding warfarin at discharge and 1 
ongoing management of patients in primary care, % (n), N = 107 2 
Statement Strongl
y agree 
 
Agree 
 
Unchanged Disagree Strongly 
disagree 
 
Missing 
 
You receive completed 
IDLs in a timely manner  
 
4.7 (5) 47.7 (51) 28.0 (30) 9.3 (10) 5.6 (6) 4.7 (7) 
The warfarin IDL has 
enabled you to better 
participate in decisions 
about warfarin dosing post-
discharge 
 
6.5 (7) 53.3 (57) 27.1 (29) 3.7 (4) 1.9 (2) 7.5 (8) 
The treatment of 
warfarinised patients is 
easier to manage post-
discharge  
 
4.7 (5) 45.8 (49) 38.3 (41) 1.9 (2) 1.9 (2) 7.5 (8) 
Warfarin stabilisation is 
easier to attain due to the 
increased information 
available on discharge 
 
3.7 (4) 35.5 (38) 49.5 (53) 2.8 (3) 0.9 (1) 7.5 (8) 
Changes to the warfarin 
IDL have resulted in 
improved safety 
 
7.5 (8) 53.3 (57) 29.0 (31) 0.9 (1) 2.8 (3) 6.5 (7) 
Changes to the warfarin 
IDL have made patients 
more aware of the risks and 
benefits of warfarin 
1.9 (2) 21.5 (23) 56.1 (60) 11.2 (12) 1.9 (2) 7.5 (8) 
 3 
4 
 11 
Table 2 – GP views on information contained within the e-proforma, % (n), N = 107 1 
Statement 
‘If the warfarin IDL has 
been completed accurately 
by hospital staff, do you 
feel that there is sufficient 
information given to allow 
for informed prescribing 
regarding…’ 
Strongly 
agree 
 
Agree 
 
Unchanged Disagree Strongly 
disagree 
 
Missing 
 
Dosing 12.1 (13) 63.6 (68) 9.3 (10) 8.4 (9) 0.9 (1) 5.6 (6) 
Indication 14.0 (15) 63.6 (68) 11.2 (12) 4.7 (5) 0.9 (1) 5.6 (6) 
Duration of treatment 8.4 (9) 56.1 (60) 17.8 (19) 10.3 (11) 0.9 (1) 6.5 (7) 
Communication of next 
expected INR test date 
10.3 (11) 66.4 (71) 8.4 (9) 6.5 (7) 2.8 (3) 5.6 (6) 
Understanding of the plan 
for treatment including 
review period 
6.5 (7) 46.7 (50) 21.5 (23) 16.8 (18) 1.9 (2) 6.5 (7) 
 2 
 3 
 4 
 5 
 6 
 7 
